文献速递系统性红斑狼疮

系统性红斑狼疮妊娠结局预测因素:系统综述与荟萃分析

Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis.
PubMed 文献 · Lancet Rheumatol · 2024-08-14

该系统综述与荟萃分析检索PubMed和Embase至2023年8月22日,纳入72项研究共8065名SLE女性的10355次妊娠,旨在明确孕前预测因素与不良妊娠结局的效应量。既往狼疮肾炎、慢性高血压、受孕时或孕前SLE疾病活动度及继发性抗磷脂综合征被识别为不良妊娠结局的预测因素,有助于优化孕前咨询中的个体化风险评估。

要点

  • 既往狼疮肾炎与活产概率降低(OR 0.62)及早产(OR 2.00)、先兆子痫(OR 3.11)风险升高相关。
  • 慢性高血压与疾病复发(OR 2.50)、早产(OR 2.65)、先兆子痫(OR 5.86)风险升高相关。
  • 继发性抗磷脂综合征与活产概率降低(OR 0.40)、20周后妊娠丢失(OR 2.77)及早产(OR 1.65)风险升高相关。

核心结论

  • 既往狼疮肾炎、慢性高血压、受孕前及受孕时SLE疾病活动度和继发性抗磷脂综合征被识别为SLE女性不良妊娠结局的预测因素。
  • 这些发现有助于在孕前咨询中进行优化的个体化风险评估。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Embase从数据库建库至2023年8月22日,纳入报告SLE孕妇孕前预测因素与方案定义结局的研究。
  • 排除样本量小于20例患者、仅限多胎妊娠、预测时间点不明确或仅报告复合结局的研究。
  • 由两名评价者独立、盲法、标准化进行文献筛选、数据提取和偏倚风险评估(预后研究质量工具)。
  • 共纳入72项研究(占6705篇唯一文章的1.1%),包含8065名SLE女性的10355次妊娠;一项可能符合条件的研究因被撤稿而移除。
  • 采用随机效应模型计算合并单变量比值比(OR)及95%CI,使用I²统计量和预测区间评估异质性;研究注册于PROSPERO,CRD42022344732。

主要发现

  • 既往狼疮肾炎与活产概率降低(OR 0.62 [95%CI 0.47-0.81];I²=0%)、早产风险升高(OR 2.00 [95%CI 1.55-2.57];I²=17%)和先兆子痫风险升高(OR 3.11 [95%CI 2.35-4.12];I²=0%)相关。
  • 慢性高血压与疾病复发风险升高(OR 2.50 [95%CI 1.74-3.58];I²=0%)、早产风险升高(OR 2.65 [95%CI 1.87-3.77];I²=0%)和先兆子痫风险升高(OR 5.86 [95%CI 3.41-10.06];I²=33%)相关。
  • 受孕时或孕前SLE疾病活动度与早产风险升高(OR 2.91 [95%CI 1.96-4.33];I²=21%)和先兆子痫风险升高(OR 2.32 [95%CI 1.40-3.83];I²=0%)相关。
  • 继发性抗磷脂综合征与活产概率降低(OR 0.40 [95%CI 0.27-0.58];I²=0%)、20周后妊娠丢失风险升高(OR 2.77 [95%CI 1.44-5.31];I²=0%)和早产风险升高(OR 1.65 [95%CI 1.29-2.11];I²=0%)相关。
  • 各研究的偏倚风险评估提示在研究减员和混杂方面存在相当程度的偏倚。

关键数值与推荐

  • 既往狼疮肾炎:活产OR 0.62(95%CI 0.47-0.81),早产OR 2.00(95%CI 1.55-2.57),先兆子痫OR 3.11(95%CI 2.35-4.12)。
  • 慢性高血压:疾病复发OR 2.50(95%CI 1.74-3.58),早产OR 2.65(95%CI 1.87-3.77),先兆子痫OR 5.86(95%CI 3.41-10.06)。
  • 受孕时或孕前SLE疾病活动度:早产OR 2.91(95%CI 1.96-4.33),先兆子痫OR 2.32(95%CI 1.40-3.83)。
  • 继发性抗磷脂综合征:活产OR 0.40(95%CI 0.27-0.58),20周后妊娠丢失OR 2.77(95%CI 1.44-5.31),早产OR 1.65(95%CI 1.29-2.11)。

临床怎么用

  • 作者认为这些发现有助于在孕前咨询中进行优化的个体化风险评估。

局限性

  • 各研究的偏倚风险评估提示在研究减员和混杂方面存在相当程度的偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To enhance patient-tailored preconception risk assessment for women with systemic lupus erythematosus (SLE), knowledge on risk factors associated with adverse pregnancy outcomes is required. Therefore, we did a systematic review and meta-analysis to identify and provide unambiguous effect sizes of preconception predictors of pregnancy outcomes in women with SLE. METHODS: In this systematic review and meta-analysis, we searched PubMed and Embase for studies reporting preconception predictors of pregnancy outcomes in women with SLE, from database inception to Aug 22, 2023. Studies were included if they presented original, quantitative data on pregnant women with SLE and reported on preconception risk factors on at least one of the outcomes as defined in the protocol. Studies were excluded if they had a sample size of less than 20 patients, were restricted to multiple pregnancies, had unclear timing of prognostication, or exclusively reported a composite outcome. Literature screening, data extraction, and risk-of-bias assessment (quality in prognostic studies tool) were done by two reviewers independently, in a blinded, standardised manner. The reported outcomes included livebirth, pre-eclampsia, small for gestational age, preterm birth, pregnancy loss before and after 20 weeks of gestation, and SLE flares. We computed pooled univariate odds ratios (ORs) and 95% CIs using a random effects model. We assessed heterogeneity using the I2 statistic and prediction intervals. This study is registered with PROSPERO, CRD42022344732. FINDINGS: Of the 6705 unique articles identified, 72 (1·1%) were included in the meta-analysis, comprising 10 355 pregnancies in 8065 women with SLE. One potentially eligible study was retracted and therefore removed from our analysis. Previous lupus nephritis was associated with decreased livebirth probability (OR 0·62 [95% CI 0·47-0·81]; I2=0%), increased risk of preterm birth (2·00 [1·55-2·57]; I2=17%), and increased risk of pre-eclampsia (3·11 [2·35-4·12]; I2=0%). Chronic hypertension was associated with increased risk of disease flare (2·50 [1·74-3·58]; I2=0%), preterm birth (2·65 [1·87-3·77]; I2=0%), and pre-eclampsia (5·86 [3·41-10·06]; I2=33%). SLE disease activity at conception or preconception was associated with increased risk of preterm birth (2·91 [1·96-4·33]; I2=21%) and pre-eclampsia (2·32 [1·40-3·83]; I2=0%). Secondary antiphospholipid syndrome was associated with decreased livebirth probability (0·40 [0·27-0·58]; I2=0%), increased risk of pregnancy loss after 20 weeks of gestation (2·77 [1·44-5·31]; I2=0%), and increased risk of preterm birth (1·65 [1·29-2·11]; I2=0%). Across studies, risk-of-bias assessment suggested considerable bias in study attrition and confounding. INTERPRETATION: We identified previous lupus nephritis, chronic hypertension, SLE disease activity before and at conception, and secondary antiphospholipid syndrome as predictors of adverse pregnancy outcomes in women with SLE. These findings contribute to an optimal patient-tailored risk assessment in preconception counselling. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wind M, Fierro JJ, Bloemenkamp KWM, et al. Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis. Lancet Rheumatol. 2024. PMID: 39153486. doi:10.1016/S2665-9913(24)00160-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。